卫生研究

参考文献

[1]毛建平,陈立军.临床肿瘤免疫治疗研究进展[J].国际药学研究杂志,2013,40(2):127-136.

[2]KALOS M,JUNE C H.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology[J].Immunity,2013,39(1):49-60.

[3]HAMID O,ROBERT C,DAUD A,et al.Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma[J].NEJM,2013,369(2):134-144.

[4]MOTZ G T,COUKOS G.Deciphering and REVERSING TUMOR IMMUNE Suppression[J].Immunity,2013,39(1):61-73

[5]SCHREIBER R D,OLD L J,SMYTH M J.Cancer immunoediting:integrating immunitys roles in cancer suppression and promotion[J].Science,2011,331(6024):1565-1570.

[6]蔡秀军,沈柏用.原发性肝癌免疫治疗进展[J].中国实用外科杂志,2011,31(8):742-744.

[7]TRAN E,TURCOTTE S,GROS A,et al.Cancer immunotherapy based on mutation-specific CD4+T cells in a patient with epithelial cancer[J].Science,2014,344(6184):641-645.

[8]BERGER M F,HODIS E,HEFFERNAN T P,et al.Melanoma genome sequencing reveals frequent PREX2 mutations[J].Nature,2012,485:502-506.

[9]MORITA D,YAMAMOTO Y,SUZUKI J,et al.Molecular requirements for T cell recognition of Nmyristoylated peptides derived from the simian immunodeficiency virus Nef protein[J].J Virol,2013,87:482-488.

[10]JIN Y,ZHANG P,LI J,et al.B7-H3 in combination with regulatory T cell is associated with tumorprogression in primary human non-small cell lung cancer[J].Int J Clin Exp Pathol,2015,8(11):13987-13995.

[11]CEDRS S,PONCE-AIX S,ZUGAZAGOITIA J,et al.Analysis of expression of programmed cell death 1ligand 1(PD-L1)in malignant pleural mesothelioma(MPM)[J].PLo S One,2015,10(3):e0121071.

[12]SAITO H,TAKAYA S,OSAKI T.Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients[J].Gastric Cancer,2013,16(4):473-479.

[13]WU G Z,PAN C X,JIANG D,et al.Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer[J].Am J Cancer Res,2015,5(9):2865-2871.

[14]VITALE M,CANTONI C,PIETRA G,et al.Effect of tumor cells and tumor microenvironment on NKcell function[J].Eur J Immunol,2014,44(6):1582-1592.

[15]YADDANAPUDI K,MITCHELL R A,EATON J W.Cancer vaccines:looking to the future[J].Oncoimmunology,2013,2(3):e23403.

[16]WHITESIDE T L,MANDAPATHIL M,SCHULER P.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells(Treg)[J].Curr Med Chem,2011,18(34):5217-5223.

[17]MITTAL S K,ROCHE P A.Suppression of antigen presentation by IL-10[J].Curr Opin Immunol,2015,34:22-27.

[18]周琳,周光炎,路丽明.IL-10的双向免疫调节作用[J].细胞与分子免疫学杂志,2012,28(10):1100-1102.

[19]COUSSENS L M,ZITVOGEL L,PALUCKA A K.Neutralizing tumor-promoting chronic inflammation:a magic bullet[J].Science,2013,339(6117):286-291.

[20]JIANG X,SHAPIRO D J.The immune system and inflammation in breast cancer[J].Mol Cell Endocrinol,2014,382(1):673-682.

[21]PRESTON C C,MAURER M J,OBERG A L,et al.The ratios of CD8+T cells to CD4+CD25+FOXP3+and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer[J].PLo S One,2013,8(11):e80063.

[22]SUNGUR C M,MURPHY W J.Positive and negative regulation by NK cells in cancer[J].Crit Rev Oncog,2014,19(1-2):57-66.

[23]RATHORE A S,GOEL M M,MAKKER A,et al.Is the tumor infiltrating natural killer cell(NK-TILs)count in infiltrating ductal carcinoma of breast prognostically significant[J].Asian Pac J Cancer Prev,2014,15(8):3757-3761.

[24]BRUNO A,FERLAZZO G,ALBINI A,et al.A think tank of TINK/TANKs:tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis[J].J Natl Cancer Inst,2014,106(8):dju200.

[25]CHANMEE T,ONTONG P,KONNO K,et al.Tumor-associated macrophages as major players in the tumor microenvironment[J].Cancers,2014,6(3):1670-1690.

[26]BENENCIA F,MUCCIOLI M,ALNAEELI M.Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies[J].Front Oncol,2014,4:72.

[27]JOHANN P D,VAEGLER M,GIESEKE F,et al.Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity[J].BMC Cancer,2010,10(1):501.

[28]WEI J,WU A,KONG L Y,et al.Hypoxia potentiates glioma-mediated immunosuppression[J].PLo S One,2011,6(1):e16195.